Renal Cancer
Transcriptome Analyses Identify an RNA Binding Protein Related Prognostic Model for Clear Cell Renal Cell Carcinoma.
February 5, 2021
The Clinical Significance of DNA Damage Repair Signatures in Clear Cell Renal Cell Carcinoma.
February 5, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
February 4, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
February 4, 2021
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
February 4, 2021
Long-Term Oncologic Outcomes After Laparoscopic and Robotic Tumor Enucleation for Renal Cell Carcinoma.
February 3, 2021
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.
February 3, 2021
Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma.
February 2, 2021
The impact of sex and age on distribution of metastases in patients with renal cell carcinoma.
February 1, 2021
Frailty predicts outcome of partial nephrectomy and guides treatment decision towards active surveillance and tumor ablation.
February 1, 2021
Development and validation of a CT-based nomogram for preoperative prediction of clear cell renal cell carcinoma grades.
February 1, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol.
January 29, 2021
A lncRNA TCL6-miRNA-155 interaction regulates the Src-Akt-EMT network to mediate kidney cancer progression and metastasis.
January 29, 2021
Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma.
January 29, 2021
Radiomics to better characterize small renal masses.
January 28, 2021